Correlation of prognostic factors of carcinoma breast with Ki 67 proliferation assay
Keywords:
Ki-67, breast carcinoma, cell proliferation, immunohistochemistry, hormone receptor statusAbstract
Prognostic factors are important for the diagnosis of breast cancer as it helps in identification of high risk patients. The objective of the study is to assess the proliferation index, Ki-67 and correlate it with other markers. The present study was a cohort study conducted in the Department of General Surgery at Tertiary Care Teaching Hospital over a period of 1 year with a sample size of 98. All the patients meeting the inclusion and exclusion criteria are recruited sequentially by convenient sampling until the sample size is attained, with the agreement of the institutional ethics committee. A total of 98 patients with a mean age of 53.61 ± 12.48 years were studied in the final analysis. The mean duration of lump was 4.62 ± 2.18 months and only 6.12% had the complaint of pain. Majority of them had stage IIIB carcinoma at 43.88%, followed by stage IIA at 27.55%, 15.31% stage IIB, 13.27% stage IIIA. At cut off 20, 69(70.40%) had ki67 proliferation index ≥20 and 29(29.59%) had<20. Correlation of Ki-67 Index with expression of estrogen receptor status had a p value of 0.019 and with progesterone receptor status, p 0.003 which was significant.
Downloads
References
Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast cancer [Internet]. 2019 Apr 10;11:151–64. Available from: https://pubmed.ncbi.nlm.nih.gov/31040712 DOI: https://doi.org/10.2147/BCTT.S176070
Zendehdel M, Niakan B, Keshtkar A, Rafiei E, Salamat F. Subtypes of Benign Breast Disease as a Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis Protocol. Iran J Med Sci. 2018 Jan;43(1):1–8.
Mavaddat N, Pharoah PDP, Michailidou K, Tyrer J, Brook MN, Bolla MK, et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015;107(5):djv036.
https://www.who.int/acessed on 6-7-21.
Leong AS, Zhuang Z. The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology. 2011;78(2):99–114. DOI: https://doi.org/10.1159/000292644
Doval DC, Sharma A, Sinha R, Kumar K, Dewan AK, Chaturvedi H, et al. Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India. Asian Pac J Cancer Prev. 2015;16(12):4959–64. DOI: https://doi.org/10.7314/APJCP.2015.16.12.4959
Kermani TA, Kermani IA, Faham Z, Dolatkhah R. Ki-67 status in patients with primary breast cancer and its relationship with other prognostic factors. Biomed Res Ther. 2019;6(2):2986–91.
Lu X, Gu Y, Ding Y, Song W, Mao J, Tan J, et al. Correlation of ER, PgR, HER-2/neu, p53, and VEGF with clinical characteristics and prognosis in Chinese women with invasive breast cancer. Vol. 14, The breast journal. United States; 2008. p. 308–10. DOI: https://doi.org/10.1111/j.1524-4741.2008.00583.x
Altintas S, Lambein K, Huizing MT, Braems G, Asjoe FT, Hellemans H, et al. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. Breast J. 2009;15(2):120–32. DOI: https://doi.org/10.1111/j.1524-4741.2009.00686.x
Baek J-M, Chae B-J, Song B-J, Jung S-S. The potential role of estrogen receptor β2 in breast cancer. Int J Surg. 2015 Feb;14:17–22. DOI: https://doi.org/10.1016/j.ijsu.2014.10.007
Kontzoglou K, Palla V, Karaolanis G, Karaiskos I, Alexiou I, Pateras I, et al. Correlation between Ki67 and breast cancer prognosis. Oncology. 2013;84(4):219–25. DOI: https://doi.org/10.1159/000346475
Juríková M, Danihel Ľ, Polák Š, Varga I. Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 2016 Jun;118(5):544–52. DOI: https://doi.org/10.1016/j.acthis.2016.05.002
Şahin S, Işık Gönül İ, Çakır A, Seçkin S, Uluoğlu Ö. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer. Int J Surg Pathol [Internet]. 2016 Jun 9;24(7):607–13. Available from: https://doi.org/10.1177/1066896916653211 DOI: https://doi.org/10.1177/1066896916653211
Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, et al. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol Off J Am Soc Clin Oncol. 2017 Apr;35(10):1061–9. DOI: https://doi.org/10.1200/JCO.2016.69.4406
Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016;13(4):496–504. DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0066
Nigam JS, Kumar T, Bharti S, Sinha R, Bhadani PP. Association of Ki-67 With Clinicopathological Factors in Breast Cancer. Cureus. 2021;13(6).
Madhushankar L, KA S, Reddy G. Analysis of Relationship between Carcinoma Breast and Expression of Ki67-A Prospective Study.
Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015;153(3):477–91. DOI: https://doi.org/10.1007/s10549-015-3559-0
Liang Q, Ma D, Gao R-F, Yu K-D. Effect of Ki-67 expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes. Sci Rep. 2020;10(1):1–9. DOI: https://doi.org/10.1038/s41598-020-64523-1
Kermani TA, Kermani IA, Faham Z, Dolatkhah R. Ki-67 status in patients with primary breast cancer and its relationship with other prognostic factors. Biomed Res Ther. 2019;6(2):2986–91. DOI: https://doi.org/10.15419/bmrat.v6i2.520
Min K-W, Kim D-H, Do S-I, Pyo J-S, Chae SW, Sohn JH, et al. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer. Postgrad Med J. 2016;92(1094):707–14. DOI: https://doi.org/10.1136/postgradmedj-2015-133531
Ragab HM, Samy N, Afify M, Abd El Maksoud N, Shaaban HM. Assessment of Ki-67 as a potential biomarker in patients with breast cancer. J Genet Eng Biotechnol. 2018;16(2):479–84. DOI: https://doi.org/10.1016/j.jgeb.2018.03.002
Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2005;26(6):281–93. DOI: https://doi.org/10.1159/000089260
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
